Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090116
Status:
COMPLETED
Last Update Posted:
2012-03-05
First Post:
2004-08-24
Brief Title:
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimers Disease
Sponsor:
Forest Laboratories
Organization:
Forest Laboratories
Study Overview
Official Title:
A Randomized Double-BlindPlacebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimers Type
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Memory loss and difficulties with thinking associated with Alzheimers disease may be due to chronic release of a brain chemical called glutamate Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor N-methyl-D-aspartate NMDA on the cell Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor NMDA receptor antagonist
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None